Laszlo Prokai
Robert A. Welch Professor
Department of Molecular Biology and Immunology
University of North Texas Health Sc...
increased proteome coverage of isolated subcellular organelles, identification of differentially expressed
proteins from c...
2. L. Prokai, X. Ouyang, W.-M. Wu, and N. Bodor, Chemical delivery system to transport a pyroglutamyl
peptide amide to the...
8, 3862–3871 (2009).
IV. RESEARCH SUPPORT
Ongoing Research Support
Estrogen-Derived Para-Quinol Intervention in Alzheimer's Disease
Principal I...
Agency: National Institute of Health/National Institute on Aging
Type: PO1 (AG027956), Period:August 15, 2007 – May 31, 20...
Co-Inventor
Systems and Methods for Evaluating Enzyme Competency, US Patent Application Serial No.
60/611,514 (UFRF)
Marke...
Mass Spectrometry-Based Proteomics for Profiling Protein Expression and Posttranslational
Modifications in Tissue, Alcon R...
Perspectives of Brain-Selective Estrogen Therapy for Neuroprotection, 4th
Pannonian
Symposium of CNS Injury (September 27,...
Application of mass spectrometry to neuropeptides and neuroproteins, University of Vienna,
Department of Analytical Chemis...
PREPARE Program
Tatjana Talamantes, 2007-2008
Lee Goodloe, 2008-2009
International Ph.D. Students (visiting UNTHSC or UF)
...
7. Interactions with Industries/Companies
Alcon Research Ltd., Fort Worth, TX: 2007–present
AgyPharma LLC, Mansfield, TX: ...
Journal of Mass Spectrometry
Journal of Medicinal Chemistry
Journal of Neurochemistry
Journal of Pharmaceutical and Biomed...
Dr. Zoltan Gombos, Biological Research Centre of the Hungarian Academy of Sciences,
Szeged, Hungary
Industrial
Dr. William...
X. FULL LIST OF PUBLICATIONS.
1. N. Rauniyar, K. Prokai-Tatrai, and L. Prokai, Identification of carbonylation sites in ap...
16. K. Prokai-Tatrai, H.S. Kim and L. Prokai, The utility of oligopeptidase in brain-targeting delivery of an
enkephalin a...
31. V. Nguyen, A.D. Zharikova, and L. Prokai, Evidence for interplay between pGlu-Glu-Pro-NH2 and thyrotropin-
releasing h...
47. S.M. Stevens, A.D. Zharikova, and L. Prokai, Proteomic analysis of the synaptic membrane fraction isolated
from rat fo...
63. L. Prokai, Prokai-Tatrai K., Zharikova, A., Li, X., Rocca, J.R., Combinatorial lead-optimization of a
neuropeptide FF ...
80. G. Somogyi, P. Buchwald, D. Nohmi, L. Prokai, and N. Bodor, Targeted drug delivery to the brain via
phosphonate deriva...
97. L. Prokai, and W.J. Simonsick, Jr., Electrospray ionization mass spectrometry coupled with size exclusion
chromatograp...
114. L. Prokai, Investigation of phenol-formaldehyde condensates by field desorption mass spectrometry, J. Polym.
Sci.: Po...
Book edited:
2. L. Prokai and K. Prokai-Tatrai, Peptide Transport and Delivery Into the Central Nervous System, Progress i...
14. L. Prokai, Zharikova, A., Nguyen, V., Li, X., Antagonism of the neurochemical effect of thyrotropin-releasing
hormone ...
Upcoming SlideShare
Loading in...5
×

Laszlo Prokai, PhD - University of North Texas

1,375

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,375
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Laszlo Prokai, PhD - University of North Texas

  1. 1. Laszlo Prokai Robert A. Welch Professor Department of Molecular Biology and Immunology University of North Texas Health Science Center Fort Worth, TX 76107 Publications Peer-reviewed: 126 Books/Books Chapters: 19 Patents: 8 h-factor: 23 University of Veszprem, Hungary B.S. 06/78 Chemical Engineering University of Veszprem, Hungary M.S. 06/80 Chemical Engineering /Radiochemical Technology University of Veszprem, Hungary Ph.D. 11/83 Radiochemistry University of Florida, Gainesville Postdoctoral 1/87 – 9/89 Medicinal Chemistry Dr. Prokai received his undergraduate (B.S.) and graduate education (M.S. and Ph.D.) from the University of Veszprém (Hungary). After a research experience under the auspices of the Hungarian Academy of Sciences mainly in the area of mass spectrometry that was recognized by the degree “Candidate of Science in Chemistry,” he joined the Department of Medicinal Chemistry at the University of Florida, Gainesville, for a postdoctoral appointment (mentor: Prof. Nicholas Bodor, a highly productive and worldwide recognized leader of medicinal chemistry in the era) in 1987. In 1989, Dr. Prokai advanced to a research faculty position at the University of Florida and, then, became an Assistant Professor at the Department of Pharmaceutics and the Center for Drug Discovery of the College of Pharmacy in 1991. During his tenure at the University of Florida, he rose in rank to Professor in the Department of Medicinal Chemistry, held an Affiliate Professorship at the Department of Chemistry, was a Joint Professor of the Department of Anesthesiology, Scientific Advisor of the Biotechnology Program, and Member of the McKnight Brain Institute. Dr. Prokai was active in the area of neuropeptide biochemistry focusing on the dynamics of their release and catabolism, as well as the biochemical regulatory role of neuropeptidases, and conceived central nervous system permeable analogues and prodrugs out of several neuropeptides for their potential exploitation as therapeutic entities (3 issued patents). In addition, his groundbreaking discoveries on free-radical scavenging and substrate preference for both the oxidation and reduction processes in a previously not recognized antioxidant cycle for estratrienes provided further opportunities for translational research of an enormous impact (5 issued patents). Dr. Prokai was recruited as the first Robert A. Welch Professor of Chemistry by the Department of Molecular Biology & Immunology of the University of North Texas Health Science Center in 2005. He has maintained an actively funded research program supported by the National Institutes of Health (NIH) and is recognized nationally and internationally for his work on discovery of, as well as bioorganic and medicinal chemistry of central nervous system agents, on neuropeptides, and in the area of proteomics and mass spectrometry. Dr. Prokai established the Advanced Mass Spectrometry and Proteomics Laboratory at the Department of Molecular Biology & Immunology, which is the most state-of-the-art facility of its kind in the Fort Worth, TX, area (considering both academia and pharmaceutical/biotechnology industry), and have pioneered the development of sophisticated methods to allow for, among others, improvement of in vivo neurochemical interrogations in the brain, obtaining
  2. 2. increased proteome coverage of isolated subcellular organelles, identification of differentially expressed proteins from cultured cells and tissue, as well as to study posttranslational protein modifications associated with oxidative stress. I. PROFESSIONAL EXPERIENCE 1980-1983 Assistant Research Scientist, Hungarian Oil and Gas Research Institute, Veszprem, Hungary 1983-1987 Associate Research Scientist, Hungarian Oil and Gas Research Institute, Veszprem, Hungary 1981-1986 Adjunct Lecturer, University of Veszprem (currently: University of Pannonia), Veszprem, Hungary 1987-1989 Postdoctoral Research Associate, Center for Drug Design and Delivery, University of Florida 1989-1990 Assistant Research Scientist, Department of Medicinal Chemistry, University of Florida 1990-1991 Assistant Scientist, Center for Drug Discovery, College of Pharmacy, University of Florida 1991-1996 Assistant Professor, Center for Drug Discovery and Dept. of Pharmaceutics, University of Florida 1996-2000 Associate Professor, Center for Drug Discovery and Dept. of Pharmaceutics, University of Florida 1998-2005 Member of the McKnight Brain Institute, University of Florida 2000-2002 Professor, Center for Drug Discovery and Dept. of Pharmaceutics, University of Florida 2001-2004 Scientific Advisor of the Biotechnology Program, University of Florida 2002-2005 Affiliate Professor, Department of Chemistry, University of Florida 2003-2005 Professor, Department of Medicinal Chemistry, University of Florida, Gainesville 2005 Joint Professor, Department of Anesthesiology, University of Florida 2005- Robert A. Welch Professor, Dept. of Molecular Biology & Immunology, UNTHSC at Fort Worth 2005-2007 Adjunct Professor, Department of Medicinal Chemistry, University of Florida 2006- Adjunct Professor, Department of Chemistry and Biochemistry, University of Texas at Arlington 2007- Department of Chemistry, Texas Christian University, Fort Worth, TX II. HONORS AND AWARDS 1993 Research Development Award, University of Florida Division of Sponsored Research 2000 Habilitation (Dr. habil.) by the University of Veszprem (currently: University of Pannonia), Veszprem, Hungary 2002 Pro Renovanda Cultura Hungariae Visiting Professorship, University of Szeged, Szeged, Hungary 2010 Doctor of Science (D. Sc., Chemistry), Hungarian Academy of Sciences, Budapest, Hungary III. SELECTED PEER-REVIEWED PUBLICATIONS (15 out of 126) 1. N. Bodor, L. Prokai, W.M. Wu, H. Farag, S. Jonalagadda, M. Kawamura, J. Simpkins. A strategy for delivering peptides into the central nervous system by sequential metabolism, Science, 257, 1698- 1700 (1992).
  3. 3. 2. L. Prokai, X. Ouyang, W.-M. Wu, and N. Bodor, Chemical delivery system to transport a pyroglutamyl peptide amide to the central nervous system, J. Am. Chem. Soc., 116, 2643-2644 (1994). 3. L. Prokai, K. Prokai-Tatrai, X. Ouyang, W.-M. Wu, H.-S. Kim, A. Zharikova, and N. Bodor, Metabolism-based brain-targeting system for a thyrotropin-releasing hormone analogue, J. Med. Chem., 42, 4563-4571 (1999). 4. L. Prokai, K. Prokai-Tatrai, and N. Bodor , Targeting drugs to the brain by redox chemical delivery systems, Med. Res. Reviews, 20, 367-416 (2000). 5. L. Prokai, K. Prokai-Tatrai, A.D. Zharikova, X. Li, and J.R. Rocca, Combinatorial lead-optimization of a neuropeptide FF antagonist, J. Med. Chem., 44, 1623-1626 (2001). 6. L. Prokai, A.D. Zharikova, T. Janáky, X. Li, A.C. Braddy, P. Perjési, L. Matveeva, D.H. Powell, and K. Prokai-Tatrai, Integration of mass spectrometry into early-phase discovery and development of central nervous system agents, J. Mass Spectrom., 36, 1211-1219 (2001). 7. L. Prokai, K. Prokai-Tatrai, A.D. Zharikova, V. Nguyen, and S.M. Stevens, Jr., Centrally-acting and metabolically stable thyrotropin-releasing hormone analogues upon replacement of histidine with substituted pyridinium, J. Med. Chem., 47, 6025-6033 (2004). 8. L. Prokai, A. Zharikova, S.M. Stevens, Jr. The effect of chronic morphine exposure on the synaptic plasma-membrane subproteome of rats: a quantitative protein profiling study based on isotope-coded affinity tags and liquid chromatography – mass spectrometry, J. Mass Spectrom., 40, 169-175 (2005). 9. N. Rivera-Portalatin, J.L. Serrano-Vera, K. Prokai-Tatrai, and L. Prokai, Comparison of estrogen- derived ortho-quinone and para-quinol concerning induction of oxidative stress, J. Steroid Biochem. Mol. Biol., 105, 71-75 (2007). 10. L. Prokai, J.W. Simpkins. Structure–nongenomic neuroprotection relationship of estrogens and estrogen-derived compounds, Pharmacol Therapeut., 114, 1-12 (2007). 11. S.M. Stevens, R.S. Duncan, P. Koulen, L. Prokai. Proteomic analysis of mouse brain microsomes: Identification and bioinformatic characterization of endoplasmic reticulum neuroproteins, J. Proteome Res., 7, 1046-1054 (2008). 12. S.M. Stevens Jr., K. Prokai-Tatrai, and L. Prokai, Factors that contribute to the misidentification of tyrosine nitration by shotgun proteomics, Mol. Cell. Proteomics, 7, 2442-2451 (2008). 13. N. Rauniyar, S.M. Stevens Jr., K. Prokai-Tatrai, L. Prokai. Characterization of 4-hydroxy-2-nonenal- modified peptides by liquid chromatography–tandem mass spectrometry using data-dependent acquisition: neutral loss-driven MS3 versus neutral loss-driven electron capture dissociation. Anal. Chem., 81, 782-789 (2009). 14. N. Rauniyar and L. Prokai, Detection and identification of 4-hydroxy-2-nonenal Schiff-base adducts along with products of Michael addition using data-dependent neutral loss-driven MS3 acquisition: method evaluation through an in vitro study on cytochrome c oxidase modifications, Proteomics, 9, 5188-5193 (2009). 15. L. Prokai, S.M. Stevens Jr., N. Rauniyar, V. Nguyen, Rapid label-free identification of estrogen- induced differential protein expression in vivo from mouse brain and uterine tissue, J Proteome Res.,
  4. 4. 8, 3862–3871 (2009).
  5. 5. IV. RESEARCH SUPPORT Ongoing Research Support Estrogen-Derived Para-Quinol Intervention in Alzheimer's Disease Principal Investigators: Mary Ann Ottinger, Ph.D.; Subcontract-PI: Laszlo Prokai, Ph.D. Agency: National Institute of Health/National Institute on Aging Type: R21 (AG031387), Period: September 15, 2009 – August 31, 2011 The goal of the proposed study is to evaluate para-quinols derived from estrone and 17β-estradiol as novel brain-selective estrogen prodrugs in a mouse model of Alzheimer’s disease as interventions for neuropathology and cognitive impairment. Novel Treatment of Menopausal Hot Flushes with an Estradiol Prodrug Principal Investigators: Istvan J. Merchenthaler, Ph.D., Laszlo Prokai, Ph.D. Agency: National Institute of Health/National Institute on Aging Type: R01 (AG031535), Period: March 1, 2009 – February 28, 2013 The long-term goal of this application is to explore the para-quinol of 17β-estradiol for estrogen therapy and, specifically, amelioration of menopausal hot flushes. Mechanism of Carisoprodol Abuse Principal Investigators: Glenn H. Dillon, Ph.D., Michael Forster, Ph.D., Laszlo Prokai, Ph.D. Agency: National Institute of Health/National Institute on Drug Abuse Type: RO1 (DA022370), Period: July 1, 2009 – June 30, 2013 The overall goal of the proposed study is to identify the mechanisms that mediate carisoprodol abuse, both at behavioral and molecular levels. Rapid Response Program for Detection of Biological and Chemical Warfare Agents Principal Investigator: Laszlo Prokai, Ph.D. Agency: US Army RDECOM Acq. Ctr. Type: Research Contract (W911SR-07-C-0050), Period: September 30, 2007 – June 21, 2010 The objective is to establish a state-of-the-art mass spectrometry facility to be used for studies on the detection and identification of potentially harmful bio-warfare and chemical agents. Survey of Age-Associated Carbonylation of Brain Proteins Principal Investigator: Laszlo Prokai, Ph.D. Agency: National Institute of Health/National Institute on Aging Type: RO1 (AG025384), Period: September 30, 2004 – August 31, 2010 The long-term objective of this project is to develop and employ a proteomic approach to facilitate the elucidation of the biochemical mechanisms that cause decrements in brain function. Effects of Age on Ethanol Withdrawal Toxicity: Mechanisms and Therapy Principal Investigator: Marianna Jung, Ph.D., Co-investigator: Laszlo Prokai, Ph.D. Agency: National Institute on Neurological Disorders and Stroke Type: RO1 (AA015982), Period: September 1, 2006 – June 30, 2011 This grant will determine mechanisms underlying deleterious interaction between ethanol withdrawal and brain aging of female subjects (rats) in the presence and absence of endogenous estrogen. Novel Mechanisms of Gonadal Hormone Action; Core B: Mass Spectrometry Program Director: Meharvan Singh, Ph.D.; Core Director: Laszlo Prokai, Ph.D.
  6. 6. Agency: National Institute of Health/National Institute on Aging Type: PO1 (AG027956), Period:August 15, 2007 – May 31, 2011 The long-term objective of this program is to identify key players in neuroprotection by estrogens and progesterone. The Mass Spectrometry Core supports four projects with proteomics. Completed during the last three years Pilot Proteomics Project Principal Investigator: Laszlo Prokai, Ph.D. Sponsor: Alcon Research Ltd. Period: May 1, 2008 – November 31, 2007 This sponsored research was focused on proteomics of cultured glaucomatous trabecular meshwork cells. The Role of Quinols in Estrogen Neuroprotection Principal Investigator: Laszlo Prokai, Ph.D. Agency: National Institute on Neurological Disorders and Stroke Type: RO1 (NS 44765, Years 1-5), Period: January 15, 2003 – December 31, 2007 The objective was to investigate neuroprotective mechanisms of estrogens as antioxidants. V. PATENTS Sole Inventor Antagonists of RF-Amide Neuropeptides, US Patent 6,797,707 (UFRF) Antagonists of RF-Amide Neuropeptides, US Patent 6,960,574 (UFRF) Thyrotropin-Releasing Hormone Analogues and Their Therapeutic Applications, US Patent 7,067,257 (UFRF) Lead Inventor Steroidal Quinols and Their Use for Antioxidant Therapy, US Patent 7,026,306 (UFRF) Prodrugs for Use as Ophthalmic Agents, US Patent 7,186,707 (UFRF) Steroidal Quinols and Their Use for Estrogen Replacement, US Patent 7,300,926 (UFRF) Quinol compound and Pharmaceutical Composition, US Patent 7,534,779 (UFRF) Prodrugs for Use as Ophthalmic Agents, US Patent 7,572,781 (UFRF) Alkyl Ether Modified Polycyclic Compounds Having a Terminal Phenol and Uses for Protection of Cells, US Patent Application Serial No. 9/893,324 (UFRF) Isotope Labeled Dinitrophenylhydrazines and Methods for Use, US Patent Application, Serial No. 60/614,951 (UFRF)
  7. 7. Co-Inventor Systems and Methods for Evaluating Enzyme Competency, US Patent Application Serial No. 60/611,514 (UFRF) Marker Detection Method and Apparatus to Monitor Drug Compliance, US Patent Application, Serial No. 11/097,647 (UFRF) Protease-Targeted Inhibitor-Ligands to Image Neuronal Cell Damage, US Patent Application, Serial No. 60/680,282 (UFRF) HDL Particles for Delivery of Nucleic Acids, US Provisional Patent Application, Serial No. pending (UNTHSC) VI. TEACHING (last 5 years) 1. UNTHSC-FW a. Lectures or Courses – Medical 2006-2007 Cellular Science – TCOM 9110 (2 hours, 2006 and 2007) b. Lectures or Courses – Graduate Integrative Biomedical Science I: Principles of Biochemistry – BMSC 6301 (2006 Fall, 2007 Fall and 2008 Fall, 4 hours each) Special Problems: Mass Spectrometry-Based Proteomics – MOLB 5900 (2008 Spring, 2009 Spring, 16 hours each) Drug Discovery and Design – MOLB 6270 (Course director, 2008 Fall, 32 hours) Principles of Biochemistry – BMSC 5301 (2009 Fall, 10 hours) 2. Univerityof Texas at Arlington (UTA) 2008 Mass Spectrometry (Graduate Course at UTA–Chemistry&Biochemistry, 2 hours) 3. Seminars (last 5 years) a. Local and State Estrogens and Neuroprotection: Does Chemistry Have a Role? University of North Texas, Department of Chemistry (September 11, 2009, Denton, TX). INVITED Peptide Transport and Delivery into the Central Nervous System, MetroCon. Organized by the IEEE Fort Worth Section (October 10, 2007, Arlington, TX). INVITED
  8. 8. Mass Spectrometry-Based Proteomics for Profiling Protein Expression and Posttranslational Modifications in Tissue, Alcon Research Ltd. (September 26, 2007, Fort Worth, TX). INVITED The Chemical Side of Estrogen Neuroprotection, Texas Christian University, Department of Chemistry (February 3, 2007, Fort Worth, TX). INVITED Everything You Always Wanted to Know about Mass Spectrometry (But Were Afraid to Ask), University of North Texas Health Science center at Fort Worth (March 27, 2006). INVITED Advances in the Application of Mass spectrometry for Monitoring Neuropeptides and Neuropeptidases in Action, University of Texas at Arlington, Department of Chemistry and Biochemistry (January 27, 2006). INVITED b. National Perspectives of Oxidative Stress-Related Biomarker Discovery by Liquid Chromatography– Tandem Mass Spectrometry Focusing on Posttranslational Protein Carbonylation, 6th US HUPO Meeting (March 9, 2010, Denver, CO). Perspectives of Brain-Selective Estrogen Therapy for Neuroprotection, University of Maryland at Baltimore, School of Medicine, Department of Anesthesiology (October 6, 2009). INVITED Challenges and Solutions to Survey Posttranslational Protein Carbonylation by Mass Spectrometry-Based Proteomics, Posttranslational Modifications: Detection & Physiological Evaluation, An American Society for Biochemistry and Molecular Biology Meeting (October 26, 2008, Tahoe City, CA). DART at Ultrahigh Resolution (FTMS), DART Forum at the 56th ASMS Conference on Mass Spectrometry and Allied Topics (June 1, 2008, Denver, Colorado, USA). INVITED Discovery of Central Nervous System Agents in Academia: Strategies and Perspectives, Arizona State University, Department of Psychology, Tempe, AZ (October 17, 2007). INVITED Survey of Morphine’s Effect on Synaptic Membrane Proteins by Quantitative Profiling, Experimental Biology 2006 (April 4, 2006, San Francisco, California, USA). INVITED c. International Mass Spectrometry-Based Methods to Identify Posttranslational Protein Modification by Covalent Attachment of Reactive α,β-Unsaturated Aldehydes, 27th Informal Meeting on Mass Spectrometry (May 4, 2009, Retz, Austria). INVITED Application of Prodrug Strategies to Create Magic Bullets for the Treatment of CNS Maladies, 2nd World Conference on Magic Bullets (Ehrlich II) (October 4, 2008, Nürnberg, Germany). INVITED
  9. 9. Perspectives of Brain-Selective Estrogen Therapy for Neuroprotection, 4th Pannonian Symposium of CNS Injury (September 27, 2008, Pécs, Hungary). INVITED Application of In Vivo Microdialysis in Neurochemistry and CNS-Drug Research, EGIS- Servier Preclinical Research Division (September 2, 2008, Budapest, Hungary). INVITED Brain-Selective Estrogen Therapy, 1st International Conference on Drug Design and Discovery (February 6, 2008, Dubai, United Arab Emirates). INVITED Application of Analytical Separation Methods Combined with In Vivo Cerebral Microdialysis Sampling and Mass Spectrometric Detection to Study Mammalian Neurochemistry in Animal Models, 7th Balaton Symposium on High-Perforemance Separation Methods (September 6, 2007, Siófok, Hungary). Proteomics in Fort Worth, Special Meeting of the Pécs Section of Hungarian Academy of Sciences (September 4, 2007, Pécs, Hungary). INVITED Recent Advances in Mass Spectrometry-Based Proteomics and Lipidomics, Biological Research Centre of the Hungarian Academy of Sciences (May 10, 2007, Szeged, Hungary) Exploration of Posttranslational Protein Carbonylation as a Marker of Oxidative Stress by Mass Spectrometry, 25th Informal Meeting on Mass Spectrometry (May 7, 2007, Nyíregyháza-Sóstó, Hungary). INVITED Mass Spectrometry in Drug Research, Semmelweis University, School of Pharmacy, Department of Pharmaceutical Chemistry (March 2, 2007, Budapest, Hungary). INVITED Application of Mass Spectrometry in Brain Research, Chemical Research Centre of The Hungarian Academy of Sciences (February 28, 2007, Budapest, Hungary). INVITED Produg Strategies to Enhance the Effect and/or Selectivity of Central Nervous System Agents after Systemic Administration, Semmelweis University, School of Pharmacy, Department of Pharmaceutical Chemistry (October 17, 2006, Budapest, Hungary). INVITED Application of Artificial Membranes to Predict Transport Across the Blood-Brain Barrier in Early-Phase Drug Discovery, Joint Scientific Session of the Complex Drug Research, and the Organic and Drug Analysis Committees of the Hungarian Academy of Sciences (October 13, 2006, Budapest, Hungary). INVITED Proteome-Wide Exploration of Posttranslational Protein Carbonylation as a Marker of Oxidative Stress, A Joint Meeting of 2nd Basic and Clinical Immunogenomics and 3rd Immunoinformatics (Immunomics) Conferences (October 10, 2006, Budapest, Hungary). INVITED Effect of Morphine on Synaptic Membrane Proteins by Quantitative Protein Profiling, International Narcotics Research Conference (INRC) 2006 (July 11, 2006, St. Paul, Minnesota, USA). INVITED
  10. 10. Application of mass spectrometry to neuropeptides and neuroproteins, University of Vienna, Department of Analytical Chemistry (June 12, 2006, Vienna, Austria). INVITED State-of-the-Art Methods of Proteomics and Their Use in Pharmaceutical Research, Congressus Pharmaceuticus Hungaricus XIII (May 26, 2006, Budapest, Hungary). INVITED 4. Student Supervision Graduate Advisor Biochemistry and Molecular Biology Program, Graduate School of Biomedical Sciences, UNTHSC, 10/2010 to present Pharmaceutical Sciences Program, College of Pharmacy, University of Florida, Gainesville, 1996–2000. Major professor (UNTHSC) Navin Rauniyar, 2005-2010: Mass spectrometry-based characterization of posttranslational modifications by 4-hydroxy-2-nonenal (Ph.D.) Victor Villarreal, 2007-2008: Structure–activity relationships of antibacterial agents. Jia Guo, 2008-present: Protein nitration and carbonylation (Ph.D.) Tatjana Talamantes, 2009-present: Proteomics in zebrafish models (Ph.D.) Lokesh Dalasanur Nagaprashan (joint with S. Awasthi), 2009-present: RLIP in cancer (Ph.D.) University of Florida: Ho-Seung Kim (Ph.D.), 1994-1997 April C. Braddy (Ph.D.), 2000-2004 Vien Nguyen (Ph.D.), 1999-2006 Tamara Blagojevic (Ph.D., joint with John Eyler, Dept. of Chemistry), 2004-2005 Nilka M. Rivera-Portalatin (Ph.D.), 2003-2006 Xiaoli Wang (Ph.D.), 2003-2006 Committee member (UNTHSC) Deepanwita Pal - 2008 UNTHSC (A. Basu) UNTHSC Summer Program Deondra Manning, 2006 Darius Bonds, 2007, 2008 Giang Nguyen, 2009
  11. 11. PREPARE Program Tatjana Talamantes, 2007-2008 Lee Goodloe, 2008-2009 International Ph.D. Students (visiting UNTHSC or UF) Rui M.M. Branca, November-December 2006, Biological Research Centre of the Hungarian Academy of Sciences, Szeged, Hungary Hajnalka Laczko-Dobos, April-May 2008, Biological Research Centre of the Hungarian Academy of Sciences, Szeged, Hungary Meritxell Teixidó, Fall 2003 (at the University of Florida), Universidad Barcelona, Spain Undergraduate Student Darius Bonds (University of Texas at Arlington), 2007-2009 High-School Student Ashwin Chandra (Coppell High School, Coppell, TX), 2009-2010 Postdoctoral Associates (in chronological order) Dr. Balazs Blazics, Semmelweis University, Hungary Dr. Srinivas Chakravartula, Osmania University, India Dr. Xiaoqian Liu, University of Missouri-Rolla Dr. Rui M. M. Branca, University of Szeged, Hungary Dr. Petr Frycak, Palacký University, Olomouc, Czech Republic Dr. Attila Kiss, University of Debrecen, Hungary Dr. Krisztina Konya, University of Debrecen, Hungary Dr. Vien Nguyen, University of Florida, Gainesville Dr. C. Mirela Stefan, University of Florida, Gainesville (at UF) Dr. Laurent Marc, CERN, Paris, France (at UF) Dr. Taewook Kim, Korea Institute of Science and Technology, Seoul, Korea (at UF) Dr. Stanley M. Stevens, Jr., University of Florida, Gainesville (at UF) Dr. Csaba Somlai, University of Szeged, Hungary (at UF) Dr. Pal Perjesi, University of Pécs, Hungary (at UF) Dr. Tamas Janaky, University of Szeged, Hungary (at UF) Dr. Alevtina Zharikova, Institute of Biological Physics, Pushchino, Russia (at UF) Dr. Seung-Woon Myung, Korea Institute of Science and Technology, Seoul, Korea (at UF) Dr. Ragulan Ramanathan, University of Florida, Gainesville (at UF) 6. Interactions with Other Institutions University of Florida, Gainesville, Department of Anesthesiology. Courtesy appointment (since 2005). This collaboration is focused on exhaled breath-based diagnostics. University of Texas at Arlington, Department of Chemistry, Adjunct appointment (since 2006). The goal is to collaborate with chemistry and biochemistry faculty and guest lecture in graduate courses. Texas Christian University, Department of Chemistry, Adjunct appointment (since 2007). The goal is to collaborate with biochemistry faculty.
  12. 12. 7. Interactions with Industries/Companies Alcon Research Ltd., Fort Worth, TX: 2007–present AgyPharma LLC, Mansfield, TX: 2008–present Tensive Controls, Inc., Greensboro, NC: 2009–present VII. SERVICE 1. UNTHSC committee memberships Graduate Council, UNTHSC, Fort Worth, 2009–present 2. Professional service -- local, state, national, international American Chemical Society Dallas/Fort Worth Section, Member of the Award Committee, 2007– 2009 American Chemical Society Dallas/Fort Worth Section, Chair of the Award Committee, 2010 Editorial Advisory Board Member, CNS Agents in Medicinal Chemistry, 2000– Editorial Advisory Board Member, Current Drug Delivery, 2003– Editorial Advisory Board Member, Medicinal Chemistry, 2004– Editorial Advisory Board Member, Medicinal Chemistry Reviews Online, 2003–2005 Editorial Advisory Board Member, Current Medicinal Chemistry, 2006– Editorial Advisory Board Member, Open Medicinal Chemistry Journal, 2007– 3. Community service None. VIII. PROFESSIONAL ACTIVITIES 1. Journal reviewer Amino Acids Analytical Chemistry Brain Research Bioorganic & Medicinal Chemistry Bioorganic & Medicinal Chemistry Letters Cellular and Molecular Neurobiology Chemical Research in Toxicology Drug Discovery Today European Journal of Pharmaceutical Sciences Free Radical Biology and Medicine International Journal of Molecular Sciences Journal of the American Society for Mass Spectrometry Journal of Chromatography Journal of Heterocyclic Chemistry
  13. 13. Journal of Mass Spectrometry Journal of Medicinal Chemistry Journal of Neurochemistry Journal of Pharmaceutical and Biomedical Analysis Journal of Pharmaceutical Sciences Journal of Proteome Research Proceedings of the National Academy of Sciences U.S.A. Rapid Communications in Mass Spectrometry Talanta 2. Grant review / study section 2000 American Chemical Society Petroleum Research Fund 2001 Board of Regents, State of Louisiana 2007 National Science Foundation 2008 Kentucky Science and Engineering Foundation (KSEF) 2009, Ad hoc Member, ETTN-A Special Emphasis Panel, NIH 2009 to present, Member, NIH Molecular Neurogenetics (MNG) Study Section 2010, Ad hoc Member, EMNR-E (10) B Special Emphasis Panel . 3. Consultantion Consultant, Du Pont Marshall Laboratory, Philadelphia, PA, 1994–2004 Consultant, Pharmos Corporation, Alachua, FL, 1994–1996 Consultant, Shaman Pharmaceuticals, South San Francisco, CA, 1997–1998 Consultant, ALS-Therapy Development Foundation, Newton, MA, 2000–2005 Co-Founder and Senior Research Officer, NeurAl-Pro, Alachua, FL, 2003–2005 Co-Founder and Chief Scientific Officer, AgyPharma LLC, Mansfield, TX, 2007– IX. PROFESSIONAL COLLABORATIONS (include collaboration that resulted in publications and/or grants or grant applications) Academic Prof. Raymond J. Bergeron, Universityof Florida, Gainesville, FL Prof. Heather A. Bimonte-Nelson, Arizona State University, Tempe, AZ Prof. Angela Brodie, Universityof Maryland, Baltimore, MD Prof. Cheryl Conrad, Arizona State University, Tempe, AZ Prof. Kenneth A. Gruber, California State Polytechnic University-Pomona, CA Prof. Peter Koulen, Universityof Missouri–Kansas City Prof. Tamas Lorand, Universityof Pécs, Hungary Prof. Walter J. McConathy, Texas Tech UniversityHealth Sciences Center Perminan Basin Campus, Odessa, TX Prof. Istvan J. Merchenthaler, Universityof Maryland, Baltimore, MD Prof. Robert A. Mericle, Vanderbilt University, Nashville, TN Prof. Mary Ann Ottinger, Universityof Maryland, College Park, MD Prof. Anil Sood, M.D. Anderson Cancer center, Houston, TX Prof. Istvan Toth, Universityof Queensland, Australia Dr. Csaba Bagyinka, Biological Research Centre of the Hungarian Academy of Sciences, Szeged, Hungary
  14. 14. Dr. Zoltan Gombos, Biological Research Centre of the Hungarian Academy of Sciences, Szeged, Hungary Industrial Dr. William J. Simonsick, Jr., Du Pont, Wilmington, DE Dr. Jeyanthi Ramasubbu, ALS-TDF, Newton, MA Dr. Emil Pop, Pharmos Corporation, Alachua, FL (now at Alchem Laboratories, Alachua, FL)
  15. 15. X. FULL LIST OF PUBLICATIONS. 1. N. Rauniyar, K. Prokai-Tatrai, and L. Prokai, Identification of carbonylation sites in apomyoglobin after exposure to 4-hydroxy-2-nonenal by solid-phase enrichment and liquid chromatography–electrospray ionization tandem mass spectrometry, J. Mass Spectrom., 45, 398-410 (2010). 2. B.B. Braden, J.S. Talboom, I. Crain, A.R. Simard, R.J. Lukas, L. Prokai, M. Scheldrup, B. Bowman, H. Bimonte-Nelson, The WHI progestin, medroxyprogesterone acetate, impairs memory and alters the GABAergic system in aged surgically menopausal rats, Neurobiol. Learn. Mem., 93, 444-453 (2010). 3. K. Prokai-Tatrai, D.V. Bonds, and L. Prokai, Simultaneous measurement of 17-estradiol, 17-estradiol and estrone by GCisotope dilution MS/MS, Chromatographia, 71, 311-315 (2010). 4. H. Lacko-Dobos, P. Frycak, B. Ughy, I. Domonkos, W. Hajime, L. Prokai, and Z. Gombos, Remodeling of phosphatidylglycerol in Synechocystis PCC6803, Biochim. Biophys. Acta Mol. Cell. Biol. Lipids, 1801, 163-170 (2010). 5. N. Rauniyar and L. Prokai, Detection and identification of 4-hydroxy-2-nonenal Schiff-base adducts along with products of Michael addition using data-dependent neutral loss-driven MS3 acquisition: method evaluation through an in vitro study on cytochrome c oxidase modifications, Proteomics, 9, 5188-5193 (2009). 6. S. Dasgupta, L. Wasson, N. Rauniyar, L. Prokai, J. Borejdo, and J.K. Vishwanatha, Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells, Oncogene, 28, 2860-2872 (2009). 7. L. Prokai, S.M. Stevens Jr., N. Rauniyar, and V. Nguyen, Rapid label-free identification of estrogen-induced differential protein expression in vivo from mouse brain and uterine tissue, J. Proteome Res., 8, 3862-3871 (2009). 8. L. Prokai, Misidentification of nitrated peptides: Comments on Hong, S.J., Gokulrangan, G., Schöneich, C., 2007. Proteomic analysis of age dependent nitration of rat cardiac proteins by solution isoelectric focusing coupled to nanoHPLC tandem mass spectrometry. Exp. Gerontol. 42, 639–651, Exp. Gerontol., 44, 367-369 (2009). 9. K. Prokai-Tatrai, L. Prokai, J.W. Simpkins, and M.E. Jung, Phenolic compounds protect cultured hippocampal neurons against ethanol-withdrawal induced oxidative stress, Int. J. Molecular Sci., 10, 1773-1787 (2009). 10. B. Kocsis, I. Kustos, F. Kilar, A. Nyul, P.B. Jakus, S. Kerekes, V. Villarreal, L. Prokai, and T. Lorand, Antifungal unsaturated cyclic Mannich ketones and aminoalcohols: Study of mechanism of action, Eur. J. Med. Chem., 44, 1823-1829 (2009). 11. K. Prokai-Tatrai and L. Prokai, Prodrugs of thyrotropin-releasing hormone and related peptides as central nervous system agents, Molecules, 14, 633-654 (2009). 12. N. Rauniyar, S.M. Stevens Jr., K. Prokai-Tatrai, and L. Prokai, Characterization of 4-hydroxy-2-nonenal- modified peptides by liquid chromatography–tandem mass spectrometry using data-dependent acquisition: neutral loss-driven MS3 versus neutral loss-driven electron capture dissociation, Anal. Chem., 81, 782-789 (2009). 13. S.M. Stevens Jr., K. Prokai-Tatrai, and L. Prokai, Factors that contribute to the misidentification of tyrosine nitration by shotgun proteomics, Mol. Cell. Proteomics, 7, 2442-2451 (2008). 14. L. Prokai, P. Frycak, S.M. Stevens Jr., and V. Nguyen, Measurement of acetylcholine in rat brain microdialysates by LC– isotope dilution tandem MS, Chromatographia, 68, S101-S105 (2008). 15. V. Nguyen, D.V. Bonds, and L. Prokai, Measurement of hydroxyl-radical formation in the rat striatum by in vivo microdialysis and GC–MS, Chromatographia, 68, S57-S62 (2008).
  16. 16. 16. K. Prokai-Tatrai, H.S. Kim and L. Prokai, The utility of oligopeptidase in brain-targeting delivery of an enkephalin analogue by prodrug design, Open Med. Chem. J., 2, 97-100 (2008). 17. S.M. Stevens, Jr., R.S. Duncan, P. Koulen, and L. Prokai, Proteomic analysis of mouse brain microsomes: Identification and bioinformatic characterization of endoplasmic reticulum neuroproteins, J. Proteome Res., 7, 1045-1054 (2008). 18. S.K. Bhutia, S.K. Mallick, S.M. Stevens, L. Prokai, J.K. Vishwanatha, and T.K. Maiti, Induction of mitochondria-dependent apoptosis by Abrus agglutinin derived peptides in human cervical cancer cell, Toxicol. In Vitro, 22, 344-351 (2008). 19. K. Prokai-Tatrai, P. Perjesi, N. Rivera-Portalatin, J.W. Simpkins, and L. Prokai, Mechanistic investigations on the antioxidant action of a neuroprotective estrogen derivative, Steroids, 73, 280-288 (2008). 20. S.M. Stevens, Jr., N. Rauniyar, and L. Prokai, Rapid characterization of covalent modifications to rat brain mitochondrial proteins after ex vivo exposure to 4-hydroxy-2-nonenal by liquid chromatography–tandem mass spectrometry using data dependent and neutral loss-driven MS3 acquisition, J. Mass Spectrom., 42, 1599- 1605 (2007). 21. L. Prokai, L.-J. Yan, J.L. Vera-Serrano, S.M. Stevens, Jr., and M.J. Forster, Mass spectrometry-based preliminary identification of mitochondrial proteins susceptible to age-related oxidative carbonylation in the rat brain, J. Mass Spectrom., 42, 1583-1589 (2007). 22. R.M.M. Branca, G. Bodo, C. Bagyinka, and L. Prokai, De novo sequencing of a 21-kDa cytochrome c4 from Thiocapsa roseopersicina by nanoelectrospray ionization ion-trap and Fourier-transform ion-cyclotron resonance mass spectrometry, J. Mass Spectrom., 42, 1569-1582 (2007). 23. A.G. Lacko, M. Nair, L. Prokai, and W.J. McConathy, Prospects and challenges of the development of lipoprotein based drug formulations for anti-cancer drugs, Exp. Opin. Drug. Deliv., 4, 665-675 (2007). 24. N. Rauniyar, S.M. Stevens, Jr., and L. Prokai, Fourier-transform ion-cyclotron resonance mass spectrometry of covalent adducts of proteins and 4-hydroxy-2-nonenal, a reactive end-product of lipid peroxidation, Anal. Bioanal. Chem., 389, 1421-1428 (2007). 25. N. Rivera-Portalatin, J.L. Serrano-Vera, K. Prokai-Tatrai, and L. Prokai, Comparison of estrogen-derived ortho-quinone and para-quinol concerning induction of oxidative stress, J. Steroid Biochem. Mol. Biol., 105, 71- 75 (2007). 26. K. Prokai-Tatrai, N. Rivera-Portalatin, N. Rauniyar, and L. Prokai, A facile microwave-assisted synthesis of p- quinols by lead(IV) acetate oxidation, Lett. Org. Chem., 4, 265-267 (2007). 27. A. Lacko, D.R. Stewart, R. McClain, L. Prokai, and W.J. McConathy, Recent developments and patenting of lipoprotein based formulations, Rec. Pat. Drug Deliv. Formul., 1, 143-145 (2007). 28. L.-J. Yan, S.-H. Yang, H. Shu, L. Prokai, and M.J. Forster, Histochemical staining and quantification of dihydrolipoamide dehydrogenase diaphorase activity using blue native PAGE, Electrophoresis, 28, 1036-1045 (2007). 29. M. Teixido, K. Prokai-Tatrai, X. Wang, V. Nguyen, and L. Prokai, Exploratory neuropharmacological evaluation of a bridged thyrotropin-releasing hormone analogue, Brain Res. Bull., 73, 103-107 (2007). 30. L. Prokai, and J.W. Simpkins, Structure–non-genomic neuroprotection relationship of estrogens and estrogen- derived compounds, Pharmacol. Therapeut., 114, 1-12 (2007).
  17. 17. 31. V. Nguyen, A.D. Zharikova, and L. Prokai, Evidence for interplay between pGlu-Glu-Pro-NH2 and thyrotropin- releasing hormone in the brain, Neurosci. Lett., 415, 64-67 (2007). 32. S. Yang, L. Prokai, and J.W. Simpkins, Correspondence regarding Schwend and Gustafsson, "False positives in MALDI-TOF detection of ER beta in mitochondria," Biochem. Biophys. Res. Commun., 345, 917-918 (2006). 33. L. Prokai, A.D. Zharikova, A. Juhasz, and K. Prokai-Tatrai, Cardiovascular effects of neuropeptide FF antagonists, Peptides, 27, 1015-1019 (2006). 34. R.A. Mericle, E.O. Richter, E. Eskioglu, C. Watkins, L. Prokai, and C.S. Santra, Preoperative endovascular brain mapping: Preliminary concept and feasibility in animal models, J. Neurosurg., 104, 566-573 (2006). 35. L. Prokai, K. Prokai-Tatrai, P. Perjesi and J.W. Simpkins, Mechanistic insights into the direct antioxidant effects of estrogens, Drug Dev. Res., 66, 118-125 (2006). 36. S.M. Stevens Jr., A.Y. Chung, M.C. Chow, S.H. McClung, C.N. Strachan, A.C. Harmon, N.D. Denslow, and L. Prokai, Enhancement of phosphoprotein analysis using a fluorescent affinity tag and mass spectrometry, Rapid Commun Mass Spectrom., 19, 2157-2162 (2005). 37. R.J. Bergeron, N. Bharti, J. Wiegand, J.S. McManis, H. Yao and L. Prokai, Polyamine-vectored iron chelators: The role of charge, J. Med. Chem., 48, 4120-4137 (2005). 38. K. Prokai-Tatrai, M. Teixido, V. Nguyen, A.D. Zharikova, and L. Prokai, A pyridinium-substituted analogue of the TRH-like tripeptide pGlu-Glu-Pro-NH2 and its prodrugs as central nervous system agents, Med. Chem., 1, 141-152 (2005). 39. J.W. Simpkins, J. Wang, X. Wang, E. Perez, L. Prokai, and J.A. Dykens, Mitochondria play a central role in estrogen-induced neuroprotection, Curr. Drug Targets, 4, 69-83 (2005). 40. L. Prokai, A.D. Zharikova, and S.M. Stevens, Jr., The effect of chronic morphine exposure on the synaptic plasma-membrane subproteome of rats: A differential proteomics study, J. Mass Spectrom., 40, 169-175 (2005). 41. S.M. Stevens, Jr., K. Prokai-Tatrai, and L. Prokai, Screening of combinatorial libraries for substrate preference by mass spectrometry, Anal. Chem., 77, 698-701 (2005). 42. L. Prokai, K. Prokai-Tatrai, A.D. Zharikova, V. Nguyen, and S.M. Stevens, Jr., Centrally-acting and metabolically stable thyrotropin-releasing hormone analogues upon replacement of histidine with substituted pyridinium, J. Med. Chem., 47, 6025-6033 (2004). 43. B.P. Ross, A.C. Braddy, R.P. McGeary, J.T. Blanchfield, L. Prokai, and I. Toth, Membrane partitioning and micellar aggregation of bile salts, fatty acids, sds, and sugar conjugated fatty acids: correlation with hemolytic activity. Mol. Pharmaceut., 1, 233-245 (2004). 44. S. Yang, R. Liu, E. J. Perez, Y. Wen, S.M. Stevens, Jr., T. Valencia, A.-M. Brun-Zinkernagel, L. Prokai, Y. Will, J. Dykens, P. Koulen, and J.W. Simpkins, Mitochondrial localization of estrogen receptor beta, Proc. Natl. Acad. Sci., 101, 4130-4135 (2004). 45. T. Lorand, E. Ôsz, G. Kispál, G. Nagy, E. Weckert, D. Luebbert, A. Meents, B. Kocsis, and L. Prokai, Diastereoselective reduction of cyclic bioactive Mannich ketones, Arch. Org. Chem. (ARKIVOC), 7, 34–52 (2004). 46. W.R. Kem, V.M. Mahnir, L. Prokai, R.L. Papke, X. Cao, S. Le Francais, K. Wildeboer, K. Prokai-Tatrai, J. Porter-Papke, and F. Soti, Hydroxy metabolites of the Alzheimer's drug candidate DMXBA (GTS-21): Their molecular properties, interactions with brain nicotinic receptors, and brain penetration, Mol. Pharmacol., 65, 56-67 (2004).
  18. 18. 47. S.M. Stevens, A.D. Zharikova, and L. Prokai, Proteomic analysis of the synaptic membrane fraction isolated from rat forebrain, Mol. Brain Res., 117, 116-128 (2003). 48. L. Prokai, K. Prokai-Tatrai, P. Perjesi, A.D. Zharikova, E. Perez, R. Liu, and J.W. Simpkins, Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection, Proc. Natl. Acad. Sci., 100, 11741–11746 (2003). 49. L. Prokai, K. Prokai-Tatrai, P. Perjesi, A.D. Zharikova, and J.W. Simpkins, Quinol-based bioreversible metabolic cycle for estrogens in rat liver microsomes, Drug Metabol. Disp., 31, 701-704 (2003). 50. K. Prokai-Tatrai, V. Nguyen, A.D. Zharikova, A.C. Braddy, S.M. Stevens, Jr., and L. Prokai, Prodrugs to enhance central nervous system effects of the TRH-like peptide pGlu-Glu-Pro-NH2, Bioorg. Med. Chem. Lett., 13, 1011-1014 (2003). 51. P. Perjesi, T. Kim, A. Zharikova, X. Li, T. Ramesh, J. Ramasubbu, and L. Prokai, Determination of clodronate content in liposomal formulation by capillary zone electrophoresis, J. Pharmaceut. Biomed. Anal., 31, 929-935 (2003). 52. S.M. Stevens, Jr., W.R. Kem, and L. Prokai, Investigation of cytolysin variants by peptide mapping: Enhanced protein characterization using complementary ionization and mass spectrometric techniques, Rapid Commun. Mass Spectrom., 16, 2094-2101 (2002). 53. T. Lorand, B. Kocsis, P. Sohar, G. Nagy, P. Jozsef, G. Kispal, R. Laszlo, and L. Prokai, Synthesis and antibacterial effect of fused Mannich ketones, Eur. J. Med. Chem., 37, 803-812 (2002) 54. K. Prokai-Tatrai, P. Perjesi, A.D. Zharikova, X. Li, and L. Prokai, Design, synthesis and biological evaluation of novel, centrally-acting thyrotropin-releasing hormone analogues, Bioorg. Med. Chem. Lett., 12, 2171-2174 (2002). 55. R. Liu, S.-H. Yang, E. Perez, K. D. Yi, S.S. Wu, K. Eberst, L. Prokai, K. Prokai-Tatrai, Z.Y. Cai, D.F. Covey, A.L. Day, and J. W. Simpkins, Neuroprotective effects of a novel non-receptor binding estrogen analogue: In vitro and in vivo analysis, Stroke, 33, 2485-2491 (2002). 56. T. Lorand, P. Forgo, A. Földesi, E. Ôsz, and L. Prokai, Improved solvent-free synthesis and structure elucidation of (E)- and (Z)-4-arylmethylene-3-isochomanones, Eur. J. Org. Chem., 2996-3003 (2002). 57. L. Prokai, and A. Zharikova, Neuropharmacodynamic evaluation of a centrally active thyrotropin-releasing hormone analogue [Leu2]TRH and its chemical brain-targeting system, Brain Res., 952, 268-274 (2002). 58. A.C. Braddy, T. Janaky, and L. Prokai, Immobilized artificial membrane chromatography coupled with atmospheric pressure ionization mass spectrometry, J. Chromatogr. A, 966, 81-87 (2002). 59. A. Zharikova, S. Zharikov, E. Block, L. Prokai, Metabolism of dynorphin A1-8 by peptidases of the pulmonary artery endothelial cells, Endothelium, 9, 37-44 (2002). 60. L. Prokai, Zharikova, A., Janáky T., Li, X., Braddy, A.C., Perjési P., Matveeva, L., Powell, D.H., Prokai-Tatrai K., Integration of mass spectrometry into early-phase discovery and development of central nervous system agents, J. Mass Spectrom., 36, 1211-1219 (2001). 61. Y. Liang, S. Belford, F. Tang, J.W. Simpkins, L. Prokai, J.A. Hughes, Membrane fluidity effects of estratrienes, Brain Res. Bull., 54, 661-668 (2001). 62. L. Prokai, Characterization of macromolecules by electrospray ionization mass spectrometry, Int. J. Polym. Anal. Charact., 6, 379-391 (2001).
  19. 19. 63. L. Prokai, Prokai-Tatrai K., Zharikova, A., Li, X., Rocca, J.R., Combinatorial lead-optimization of a neuropeptide FF antagonist, J. Med. Chem., 44, 1623-1626 (2001). 64. L. Prokai, Oon, S.-M., Prokai-Tatrai K., Abboud, K.A., Simpkins, J.W., Synthesis and biological evaluation of 17-alkoxyestra-1,3,5(10)-trienes as potential neuroprotectants against oxidative stress, J. Med. Chem., 44, 110-114 (2001). 65. Benedek Cs., L. Prokai, Törös Sz., Heil B., Diastereoselective hydroalkoxycarbonylation of terpenes and vinyl- estrone, J. Mol. Catal. A, 165, 15-21 (2001). 66. L. Prokai, Zharikova, A., Janáky T., Prokai-Tatrai K., Exploratory pharmacokinetics and brain distribution study of a neuropeptide FF antagonist by liquid chromatography/atmospheric pressure ionization tandem mass spectrometry, Rapid Commun. Mass Spectrom., 14, 2412-2418 (2000). 67. L. Prokai, K. Prokai-Tatrai, and N. Bodor , Targeting drugs to the brain by redox chemical delivery systems, Med. Res. Reviews, 20, 367-416 (2000). 68. S.-H. Yoon, J. Wu, W.-M. Wu, L. Prokai, and N. Bodor, Brain-targeted chemical delivery of [Leu2, Pip3]-TRH: Synthesis and biological evaluation, Bioorg. Med. Chem., 8, 1059-1063 (2000). 69. L. Prokai, K. Prokai-Tatrai, X. Ouyang, W.-M. Wu, H.-S. Kim, A. Zharikova, and N. Bodor, Metabolism-based brain-targeting system for a thyrotropin-releasing hormone analogue, J. Med. Chem., 42, 4563-4571 (1999). 70. D. J. Aaserud, L. Prokai, and W. J. Simonsick, Jr., Gel permeation chromatography coupled to Fourier transform mass spectrometry for polymer characterization, Anal. Chem., 71, 4793-4799 (1999). 71. L. Prokai and K. Prokai-Tatrai, Metabolism-based drug design and drug targeting, Pharm. Sci. Tech. Today, 2, 457-463 (1999). 72. E. Pop, S. Rachwal, J. Vlasak, A. Biegon, A. Zharikova, and L. Prokai, In vitro and in vivo study of some water-soluble prodrugs of dexanabinol, J. Pharm. Sci., 88, 1156-1160 (1999). 73. G. Brazeau, J. Hughes, and L. Prokai, Use of problem based discussion sessions in a first year pharmaceutical dosage forms course, Am. J. Pharm. Educ., 63, 85-97 (1999). 74. L. Prokai, D.J. Aaserud, and W.J. Simonsick, Jr., Microcolumn size-exclusion chromatography coupled with electrospray ionization mass spectrometry, J. Chromatogr., 835, 121-126 (1999). 75. L. Prokai and A. Zharikova, Identification of synaptic metabolites of dynorphin A (1-8) by electrospray ionization and tandem mass spectrometry, Rapid Commun. Mass Spectrom.,12, 1796-1800 (1998). 76. E. Pop., B. Rachwal, S. Rachwal, J. Vlasak, M. Brewster, and L. Prokai, Synthesis of deuterated dexanabinol, J. Labeled Comp. Radiopharm., 41, 885-897 (1998). 77. L. Prokai, H.-S. Kim, J. Roboz, L. Ma, and L. Deng, Electrospray ionization mass spectrometric studies on the metabolism of synthetic dynorphin A peptides in brain tissue in vitro and in vivo, J. Chromatogr., 800, 59-68 (1998). 78. P. Chen, N. Bodor, W.-M. Wu, and L. Prokai, Strategies to target kyotorphin analogs to the brain, J. Med. Chem., 41, 3773-3781 (1998). 79. N. Bodor, K. Prokai-Tatrai, E. Koltai, and L. Prokai, Preparation of o-(3,3,8,10,10-pentamethyl-1,2-dithia-5,8- diaza-cyclodecan-5-yl)-ethyl-o-pivaloyloxymethylene-p-phenylphosphonate: Potential synthetic precursor for ligands of a 99mTc-labeled brain-imaging agent, Org. Prep. Proc. Int., 30, 521-525 (1998).
  20. 20. 80. G. Somogyi, P. Buchwald, D. Nohmi, L. Prokai, and N. Bodor, Targeted drug delivery to the brain via phosphonate derivatives II. Anionic chemical delivery system for zidovudine (AZT), Int. J. Pharm., 166, 27-35 (1998). 81. G. Somogyi, S. Nishitani, D. Nohmi, P. Buchwald, L. Prokai, and N. Bodor, Targeted drug delivery to the brain via phosphonate derivatives I. Design, synthesis and evaluation of an anionic chemical delivery system for testosterone, Int. J. Pharm., 166, 15-26 (1998). 82. L. Prokai, X. Ouyang, K. Prokai-Tatrai, J.W. Simpkins, and N. Bodor, Synthesis and behavioral evaluation of a chemical brain-targeting system for a thyrotropin-releasing hormone analogue, Eur. J. Med. Chem., 33, 879-886 (1998). 83. N. Bodor, H. Farag, G. Somogyi, W.-M. Wu, M.D.C. Barros, and L. Prokai, Ocular-specific delivery of timolol by sequential bioactivation of its oxime and methoxime analogs, J. Ocular Pharm. Ther., 13, 389-403 (1997). 84. H. Farag, W.-M. Wu, M.D.C. Barros, G. Somogyi, L. Prokai, and N. Bodor, Ocular-specific chemical delivery systems for betaxolol for safe local treatment of glaucoma, Drug Design Discov., 15, 117-130 (1997). 85. G. Osapay, L. Prokai, H.-S.Kim, K. F. Medzihradszky, D. H. Coy, G. Liapakis, T. Reisine, G. Melacini, Q. Zhu, S. H.-H. Wang, R.-H. Mattern, and M. Goodman, Lanthionine-somatostatin analogs, characterization, biological activity and enzymatic stability studies, J. Med. Chem. 40, 2241-2251 (1997). 86. L. Prokai, Peptide delivery into the central nervous system: invasive, physiological and chemical approaches, Exp. Opin. Ther. Patents, 7, 233-245 (1997). 87. L. Prokai, R. Ramanathan, J. Nawrocki, and J. Eyler, Electrospray ionization mass spectrometry of cyclodextrin complexes of amino acids and peptides, J. Incl. Phenom. Mol. Recogn., 25, 117-120 (1996). 88. L. Prokai, Delivery of peptides into the central nervous system, Drug Discovery Today 1, 161-168 (1996). 89. K. Prokai-Tatrai, L. Prokai, and N. Bodor, Brain-targeting of a leucine-enkephaline analogue by retrometabolic design, J. Med. Chem., 39, 4775-4782 (1996). 90. N. Bodor, L. Prokai, W.-M. Wu, G. Somogyi, and H. Farag, Sequential bioactivation of methoxime analogs of ß-adrenergic antagonists in the eye, J. Ocular Pharmacol. Ther., 11, 305-318 (1995). 91. R. Ramanathan and L. Prokai, Electrospray ionization mass spectrometric study of encapsulation of amino acids by cyclodextrins, J. Am. Soc. Mass Spectrom., 6, 866-871 (1995). 92. L. Prokai, W.-M. Wu, G. Somogyi, and N. Bodor, Ocular delivery of the beta-adrenergic antagonist alprenolol by sequential bioactivation of its metoxime analogue, J. Med. Chem., 38, 2018-2020 (1995). 93. L. Prokai, Analytical challenges in chemical-enzymatic drug targeting, Adv. Drug Delivery Rev., 14, 301-317 (1994). 94. J.W. Simpkins, X. Ouyang, L. Prokai, and N. Bodor, Delivery of peptides into the central nervous system by molecular packaging and sequential metabolism as a method to alter neuropeptide activity during aging, Neuroprotocols: A Companion to Methods in Neuroscience , 4, 225-234 (1994). 95. V. Larsimont, L. Prokai, and G. Hochhaus, Leucine enkephalin - tyrosinase reaction products: Identification by mass spectrometry and biological activity, Biochim. Biophys. Acta, 1222, 95-100 (1994). 96. L. Prokai, X. Ouyang, W.-M. Wu, and N. Bodor, Chemical delivery system to transport a pyroglutamyl peptide amide to the central nervous system, J. Am. Chem. Soc., 116, 2643-2644 (1994).
  21. 21. 97. L. Prokai, and W.J. Simonsick, Jr., Electrospray ionization mass spectrometry coupled with size exclusion chromatography, Rapid Commun. Mass Spectrom., 7, 853-856 (1993). 98. L. Prokai, K. Prokai-Tatrai, E. Pop, N. Bodor, J. Roboz, and J. Lango, Fast atom bombardment and tandem mass spectrometry of quaternary pyridinium-substituted tryptophans, Org. Mass Spectrom., 28, 707-715 (1993). 99. L. Prokai, and W.J. Simonsick, Jr., Direct mass spectrometric analysis of phenol-formaldehyde oligocondensates: A comparative desorption ionization study, Macromolecules, 25, 6532-6539 (1992). 100. N. Bodor, L. Prokai, W.M. Wu, H. Farag, S. Jonalagadda, M. Kawamura, and J. Simpkins, A strategy for delivering peptides into the central nervous system by sequential metabolism, Science, 257, 1698-1700 (1992). 101. N. Bodor, and L. Prokai, Intermediates of the borane reduction of some imidazolidines: An AM1 Study, Int. J. Quant. Chem., 44, 795-805 (1992). 102. N. Bodor, E. Koltai, and L. Prokai, Borohydride reduction of imidazolidino-[1,2-d]dithiazepines, Tetrahedron, 48, 4767-4772 (1992). 103. L. Prokai and N. Bodor, Reversed-phase high-performance liquid chromatography - thermospray mass spectrometry of alprenolol and its ketoxime analogues, J. Chromatogr., 541, 474-479 (1991). 104. L. Prokai, A. Simay, and N. Bodor, Reversed- phase high-performance liquid chromatography of ketoxime analogues of -adrenergic blockers, J. Chromatogr., 541, 469-473 (1991). 105. N. Bodor, and L. Prokai, Site- and stereospecific drug delivery by sequential enzymatic bioactivation, Pharm. Res., 7, 723-725 (1990). 106. G. Somogyi, Z. Dinya, and A. Lacziko,and L. Prokai, Mass spectrometric identification of thin-layer chromatographic spots: Implementation of a modified Wick-Stick technique, J. Planar Chromatogr., 3, 191-193 (1990). 107. G. Somogyi, M. Varga, L. Prokai, Z. Dinya, and L. Buris, Drug identification problems in two suicides with neuromuscular blocking agents, Forensic Sci. Int., 43, 257-266 (1989). 108. A. Simay, L. Prokai, and N. Bodor, Oxidation of aryloxyaminoalcohols with activated dimethyl-sulfoxide: A novel C-N oxidation, facilitated by neighboring group effect, Tetrahedron, 45, 4091-4102 (1989). 109. L. Prokai, T. Lorand, and A. Foldesi, Mass spectra of some 2-amino-4H-3,1-benzothiazine and 2-amino-4H-pyrido[4,3-D] [1,3]thiazine derivatives, Org. Mass Spectrom., 24, 517-519 (1989). 110. L. Prokai, B.-H. Hsu, H. Farag, and N. Bodor, Desorption chemical ionization, thermospray and fast atom bombardment mass spectrometry of dihydropyridine - pyridinium salt-type redox systems, Anal. Chem., 61, 1723-1728 (1989). 111. L. Prokai, Pyrolysis - mass spectrometric investigation of the mechanistic and kinetic aspects of the thermal degradation of phenol-formaldehyde polycondensates, J. Anal. Appl. Pyrolysis, 12, 265-283 (1987). 112. L. Prokai, Preparation and mass spectrometric characterization of deuterium-labelled phenol-formaldehyde condensates, Acta Chim. Acad. Sci. Hung., 124, 901- (1987). 113. L. Prokai, and L. Bencze, Electron impact induced fragmentation of 2-carbonylated bicylco[2,2,1]heptane stereoisomers, Org. Mass Spectrom., 21, 384-386 (1986).
  22. 22. 114. L. Prokai, Investigation of phenol-formaldehyde condensates by field desorption mass spectrometry, J. Polym. Sci.: Polym. Lett., 24, 223-227 (1986). 115. L. Prokai, Separation and identification of phenol-formaldehyde condensates by gas chromatography - mass spectrometry. IV. Application of a stationary phase of intermediate polarity to the analysis of methylolated dihydroxydiphenylmethanes, J. Chromatogr., 356, 331-333 (1986). 116. L. Bencze, and L. Prokai, Novel mechanism for the carbonylation and hydroformylation of olefins via carbene and ketene type intermediates, J. Organomet. Chem., 294, C5-C8 (1985). 117. L. Bencze, A. Kraut-Vass, and L. Prokai, Mechanism of initiation of the metathesis of norbornene using W(CO)3Cl2(AsPh3)2 as catalyst, J. Chem. Soc., Chem. Commun., 911-912 (1985). 118. L. Prokai, Separation and identification of phenol-formaldehyde condensates by gas chromatography - mass spectrometry. III. Hemiformal isomers in resol, J. Chromatogr., 333, 161-166 (1985). 119. L. Prokai, Separation and identification of phenol-formaldehyde condensates by gas chromatography - mass spectrometry. II. Base-catalysed condensation products, J. Chromatogr., 331, 91-98 (1985). 120. L. Prokai, Separation and identification of phenol-formaldehyde condensates by gas chromatography - mass spectrometry. I. Acid-catalysed condensation products, J. Chromatogr., 329, 290-294 (1985). 121. J. Deli, T. Lorand, A. Foldesi, and L. Prokai, Synthesis of 2-amino-4-aryl-5,6- dihydrobenzo[h]quinazolines and their derivatives, Acta Chim. Acad. Sci. Hung., 117, 293-305 (1984). 122. L. Prokai, and J. Toth, Investigations on the evaporation phenomena in the plastic-bonded electrodes used in emission spectroscopy by radioisotope labeling, J. Radioanal. Nucl. Chem., 87, 231-238 (1984). 123. J. Toth, and L. Prokai, Study of electrodes used in emission spectrography by radioisotope labeling, Izotoptechnika, 23, 190-195 (1980). 124. J. Toth, and L. Prokai, A study of carbon electrodes, used in emission spectrography, by radioisotope labelling, Izotoptechnika, 23, 84-92 (1980). b. Full-length papers -- in press 125. E. Engler-Chiurazzi, C. Tsang, S. Nonnenmacher; W. Liang, J. Corneveaux, L. Prokai, M. Huentelman, and H.A. Bimonte-Nelson, Tonic Premarin dose-dependently enhances memory, affects neurotrophin protein and alters gene expression in middle-aged rats, Neurobiol. Aging, in press. doi:10.1016/j.neurobiolaging.2009.09.005 126. V. Nguyen, A.D. Zharikova, K. Prokai-Tatrai, and L. Prokai, [Glu2]TRH dose-dependently attenuates TRH- evoked analeptic effect in the mouse brain, Brain Res. Bull., in press. doi:10.1016/j.brainresbull.2010.02.007 c. Full-length papers -- submitted 6 d. Chapters, reviews, books Book authored: 1. L. Prokai, Field Desorption Mass Spectrometry, Practical Spectroscopy Monograph Series, Marcel Dekker, New York, 1990, pp. 304.
  23. 23. Book edited: 2. L. Prokai and K. Prokai-Tatrai, Peptide Transport and Delivery Into the Central Nervous System, Progress in Drug Research, Vol. 61, Birkhäuser, Basel, 2003, pp. 245. Book chapters: 3. L. Prokai, K. Prokai-Tatrai, W.-M. Wu, J. Wu, X. Ouyang, H.-S. Kim, A. Zharikova, J. Simpkins, and N. Bodor, Brain delivery and targeting of thyrotropin-releasing hormone analogs by covalent packaging and sequential metabolism, in Peptides: Chemistry, Structure and Biology (J.P. Tam and P.T.P. Kaumaya, Eds.), Kluver Academic, Dordrecht, The Netherlands, 1998, 834-836. 4. L. Prokai, Application of mass spectrometry in brain research: neurotransmitters, neuropeptides and brain proteins, Chapter 18 in Medical Applications of Mass Spectrometry (K. Vekey, A. Telekes, A. Vertes, Eds.), Elsevier, Amsterdam, 2008, 407-424. 5. K. Prokai-Tatrai and L. Prokai, The impact of metabolism on the safety of estrogen therapy, in Annals of the New York Academy of Sciences, Vol. 1052 (M. Singh, Ed.), New York Academy of Sciences, New York, NY, 2005, 243-257. 6. L. Prokai, S.M. Stevens, Jr., and W.J. Simonsick, Jr., Size-exclusion chromatography coupled to mass spectrometry and tandem mass spectrometry for oligomer analysis, in Multiple Detection in Size-Exclusion Chromatography (A.M. Striegel, Ed.), ACS Books, Washington, DC, 2005, 196-207. 7. L. Prokai, V. Nguyen, B.R. Jasti, and T.K. Gosh, Principles and application of surface phenomena, in Theory and Practice of Contemporary Pharmaceutics (T.K. Ghosh , B.R. Jasti, Eds.), CRC Press, Boca Raton, FL, 2004, 165-196. 8. A.M. Persky, L. Prokai, and J.A. Hughes, States of matter, in Theory and Practice of Contemporary Pharmaceutics (T.K. Ghosh, B.R. Jasti, Eds.), CRC Press, Boca Raton, FL, 2004, 31-53. 9. L. Prokai, S. M. Stevens, Jr., and K. Prokai-Tatrai, Chirality-based isotope labeling in library of substrates (CHILLS) to screen for enzyme preference by mass spectrometry. In Peptide Revolution: Genomics, Proteomics & Therapeutics (M. Chorev and T.K.Sawyer, Eds.), American Peptide Society, Cardiff, CA, 2004, 869-870. 10. K. Prokai-Tatrai and L. Prokai, Modifying peptide properties by prodrug design for enhanced transport into the CNS, in Progress in Drug Research, Vol. 61 (L. Prokai, K. Prokai-Tatrai, Eds.), Birkhäuser, Basel, 2003, 155- 188. 11. L. Prokai, Central nervous system effects of thyrotropin-releasing hormone and its analogues: opportunities and perspectives for drug discovery and development, in Progress in Drug Research, Vol. 59 (E.M. Jucker, Ed.), Birkhäuser, Basel, 2002, 133-170. 12. L. Prokai, Targeting drugs into the central nervous system, Chapter 19 in Biomedical Aspects of Drug Targeting (V. Muzykantov and V. Torchilin, Eds.), Kluwer Academic, Dordrecht, The Netherlands, 2002, 359- 380. 13. L. Prokai, Electrospray ionization and on-line LC/MS, Chapter 4 in Mass Spectrometry of Polymers (G. Montaudo and R.P. Lattimer, Eds.), CRC Press, Boca Raton, FL, 2002, 149-180.
  24. 24. 14. L. Prokai, Zharikova, A., Nguyen, V., Li, X., Antagonism of the neurochemical effect of thyrotropin-releasing hormone by its peptide analog, in Peptides: The Wave of the Future (M. Lebl and R.A. Houghten, Eds.), Kluwer Academic, Dordrecht, The Netherlands, 2002, 980-981. 15. L. Prokai and K. Prokai-Tatrai, Prodrugs, Chapter 12 in Pain, Irritation and Muscle Damage with Injectable Products, P. Gupta and G. Brazeau, Eds., Interpharm Press, Englewood, CO, 1999, 267-306. 16. L. Prokai, Peptide drug delivery into the central nervous system, in Progress in Drug Research, Vol. 51 (E.M. Jucker, Ed.), Birkhäuser, Basel, 1998, 95-131. 17. W.J. Simonsick, Jr., and L. Prokai, Size exclusion chromatography with electrospray mass spectrometric detection, Chapter 4 in Hyphenated Techniques in Polymer Characterization (T. Provder, H. Barth, M.W. Urban, Eds.), ACS Books, Washington, D.C., 1995, 41-56. 18. N. Bodor and L. Prokai, Molecular packaging: Peptide delivery to the CNS by sequential metabolism, Chapter 14 in Peptide-Based Drug Design: Controlling Transport and Metabolism (M. Taylor, G. Amidon, Eds.), ACS Books, Washington, D.C., 1995, 317-337. 19. N. Bodor and L. Prokai, Delivery of peptides into the central nervous system by sequential metabolism, in Peptides: Chemistry, Structure and Biology (R.S. Hodges and J.A. Smith, Eds.), ESCOM, Amsterdam, 1994, pp. 830-833. Book review: Prokai L. Book Review: Cancer Proteomics - From Bench to Bedside (Daoud SS, Ed.),. ChemMedChem., 4, 1949- 1951 (2009).

×